Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.

Scientific reports - 23 Aug 2017

Tan Yi-Hung Carol, Mirzapoiazova Tamara, Won Brian M, Zhu Li, Srivastava Minu K, Vokes Everett E, Husain Aliya N, Batra Surinder K, Sharma Sherven, Salgia Ravi

Abstract excerpt

Casitas B-lineage lymphoma (CBL) is an E3 ubiquitin ligase and a molecule of adaptor that we have shown is important for non-small-cell lung cancer (NSCLC). We investigated if MET is a target of CBL and if enhanced in CBL-altered NSCLC. We showed that CBL wildtype cells have lower MET expression than CBL mutant cells. Ubiquitination of MET was also decreased in CBL mutant cells compared to wildtype cells. Mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Knockdown Techniques
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proteolysis

Share to Proto-Oncogene Proteins c-cbl

Share to Proto-Oncogene Proteins c-met

Share to RNA Interference

Share to RNA, Small Interfering

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28835699
DOI: 10.1038/s41598-017-09078-4
PMCID: PMC5569108

Genes

CBL
MET
EPHA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.PMID 28835699Read ↗

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine KinasesSemantic proximity Read ↗

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategiesSemantic proximity Read ↗

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1.Semantic proximity Read ↗

Negative regulation of EGFR-Vav2 signaling axis by Cbl ubiquitin ligase controls EGF receptor-mediated epithelial cell adherens junction dynamics and cell migration.Semantic proximity Read ↗

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.Semantic proximity Read ↗

Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung AdenocarcinomaSemantic proximity Read ↗

Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesisSemantic proximity Read ↗

E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.Semantic proximity Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Semantic proximity Read ↗

Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.Semantic proximity Read ↗

Overexpression of crkl correlates with poor prognosis and cell proliferation in non‐small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.